Zacks Investment Research
10 Jun 2026, 22:50 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Top 1 mover · tap to explore
What the story claims
3 claims · each scored for market impact
Viking Therapeutics (VKTX) projected EPS for the upcoming quarter is -$1.21, a 108.62% decrease from the same period last year. — A significant year-over-year increase in losses typically weighs on investor sentiment for biotech names.
-0.60The Medical - Biomedical and Genetics industry is ranked in the bottom 37% of all industries tracked by Zacks. — Low industry ranking indicates systemic headwinds or underperformance across the sector, increasing risk for individual stocks within it.
-0.20Viking Therapeutics currently carries a Zacks Rank of #3 (Hold). — A 'Hold' rating suggests a lack of strong immediate bullish catalysts, indicating neutral to slightly negative momentum.
-0.10Which stocks this story touches
Continue reading
6 related stories
The stock underperformed the market, experienced a recent price drop, and is projecting a significant decrease in earnings per share.
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
Catch the names this kind of story moves — before the chart does.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
Zacks Investment Research
2h ago
